NOVABIO Research Profile

What Is Thymosin Alpha-1 (Tα1)?

Thymosin Alpha-1 (Tα1) is a peptide entry identified by the Thymosin Alpha-1 and Tα1 names. This page identifies the material as Thymosin Alpha-1 (TA-1), with amino acid count 28; synonyms Thymalfasin; Tα1. The Thymosin Alpha-1 (Tα1) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Exact-product regulatory reviewLast verified 2026-10-06
Catalogue identityThymosin Alpha-1 (TA-1)
Available specifications5mg, 10mg
Evidence snapshot66 trials · 583 publications
Last verified2026-10-06

What Is Thymosin Alpha-1 (Tα1)?

Thymosin Alpha-1 (Tα1) is a peptide entry identified by the Thymosin Alpha-1 and Tα1 names. This page identifies the material as Thymosin Alpha-1 (TA-1), with amino acid count 28; synonyms Thymalfasin; Tα1. The Thymosin Alpha-1 (Tα1) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

66ClinicalTrials.gov query records
583PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Thymosin Alpha-1 (Tα1) is organized around thymosin peptide characterization, immune-peptide literature, peptide signaling studies, and analytical peptide workflows. For Thymosin Alpha-1 (Tα1), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
NCT02906163First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care TherapyPhase 1/Phase 2UnknownEGFR Mutation Positive Non Small Cell Lung Cancer2016-09-19
NCT02542137Abscopal Effect for Metastatic Small Cell Lung CancerPhase 2WithdrawnSmall Cell Lung Cancer, Radiotherapy, Thymalfasin2019-03-21
NCT04524169Immunotherapy for Elderly Patients With Chronic Osteoporotic PainPhase 4UnknownOsteoporotic Pain2020-08-26
NCT00935558Dendritic Cell Based Therapy for Breast Cancer PatientsPhase 2WithdrawnBreast Cancer2012-05-31
NCT02366208Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis BPhase 2CompletedHepatitis B, Chronic2015-02-19
NCT07277439Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ AdenocarcinomaPhase 2RecruitingGastric Cancer2026-03-19

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Aging and Thymosin Alpha-1.

International journal of molecular sciences · 2025 Nov 27

PMID 41373628
Selected PubMed record

Thymosin alpha-1.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2001 May 15

PMID 11381492
Selected PubMed record

Thymosin alpha 1: A comprehensive review of the literature.

World journal of virology · 2020 Dec 15

PMID 33362999
Selected PubMed record

Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP · 2024 Dec

PMID 39648386
Selected PubMed record

Thymosin alpha 1 treatment for patients with sepsis.

Expert opinion on biological therapy · 2018 Jul

PMID 30063866
Selected PubMed record

Serum thymosin alpha 1 levels in normal and pathological conditions.

Expert opinion on biological therapy · 2018 Jul

PMID 30063864

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
Thymosin Alpha-1 (TA-1)
Available Specifications
5mg, 10mg
Pack Format
10 Vials
CAS Number
62304-98-7
Molecular Formula
C129H215N33O55
Molecular Weight
3108.30 g/mol
Amino Acid Count
28
Sequence
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
Synonyms
Thymalfasin; Tα1
Physical Form
Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 16130571 · Product form must still be matched to the catalogue and batch record.

Research Tools for Thymosin Alpha-1 (Tα1)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Thymosin Alpha-1 (Tα1) Research Summary

Identity

Thymosin Alpha-1 (TA-1); specifications: 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for Thymosin Alpha-1 (Tα1) is organized around thymosin peptide characterization, immune-peptide literature, peptide signaling studies, and analytical peptide workflows. For Thymosin Alpha-1 (Tα1), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

66 registry records and 583 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Thymosin Alpha-1 (Tα1) is represented here by the catalogue identity Thymosin Alpha-1 (TA-1). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Thymosin Alpha-1 (Tα1) is organized around thymosin peptide characterization, immune-peptide literature, peptide signaling studies, and analytical peptide workflows. For Thymosin Alpha-1 (Tα1), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 66 ClinicalTrials.gov records and 583 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Thymosin Alpha-1 (Tα1) FAQ

What is Thymosin Alpha-1 (Tα1)?

Thymosin Alpha-1 (Tα1) is a peptide entry identified by the Thymosin Alpha-1 and Tα1 names. This page identifies the material as Thymosin Alpha-1 (TA-1), with amino acid count 28; synonyms Thymalfasin; Tα1. The Thymosin Alpha-1 (Tα1) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Thymosin Alpha-1 (Tα1)?

The synchronized query returned 66 ClinicalTrials.gov records and 583 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Thymosin Alpha-1 (Tα1) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.